NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026
Go back to NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026| AbbVie (NYSE: ABBV) | Delayed: 233.78 +3.77 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $230.01 | 52 Week High | $68.12 | |||
| Open | $232.97 | 52 Week Low | $50.71 | |||
| Day High | $234.71 | P/E | 50.71 | |||
| Day Low | $231.30 | EPS | $4.61 | |||
| Volume | 2,270,324 | |||||
| (NASDAQ: LABP) | Delayed: 22.93 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.93 | 52 Week High | $ | |||
| Open | $5.45 | 52 Week Low | $ | |||
| Day High | $22.93 | P/E | N/A | |||
| Day Low | $22.93 | EPS | $ | |||
| Volume | 1,124,166 | |||||
